American Society of Clinical Oncology (ASCO) shared a post on LinkedIn:
“The landscape of thyroid cancer treatment continues to evolve. New evidence-based recommendations have been released, specifically addressing the use of systemic therapy across several key pathologies:
- Well-differentiated thyroid cancer
- Differentiated high-grade and poorly differentiated cases
- Anaplastic and Medullary thyroid cancer
For clinicians and researchers, these guidelines serve as a vital framework for navigating complex treatment decisions and optimizing systemic interventions.”
Title: Systemic Treatment of Thyroid Cancer: ASCO Guideline
Authors: Nabil F. Saba, Nofisat Ismaila, Douglas Adkins, Nishant Agrawal, Neil Akhave, Erik S. Blomain, Maria E. Cabanillas, Amy Chen, Thomas J. Galloway, Guilherme Harada, Dapeng Li, Salem I. Noureldine, Joe Scharpf, Lova L. Sun, Mei Tang, Lori Wirth, Francis Worden, Dan P. Zandberg, and Beth M. Beadle.
Other articles about American Society of Clinical Oncology (ASCO) on OncoDaily.